New Product - Xtandi
Xtandi (enzalutamide) is an androgen receptor signalling inhibitor that competitively inhibits binding of androgens to androgen receptors, and consequently inhibits the nuclear translocation of these receptors and inhibits the binding of androgen receptor to DNA. Xtandi is indicated for the treatment of patients with metastatic castration resistant prostate cancer who have previously received docetaxel. Xtandi is contraindicated in women who are, or may become, pregnant. Xtandi 40 mg capsules are available in 112’s (carton of 4 wallets, each wallet containing blisters of 28’s).
Copyright © MIMS Australia Pty Ltd. All rights reserved.
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629